OptiNose, Inc. - OPTN STOCK NEWS

OptiNose (NASDAQ:OPTN) announced the grant of non-qualified stock options to six new employees as an employment inducement. A total of 53,500 shares were awarded, with exercise prices reflecting the stock's closing prices on their respective grant dates ($2.64 and $1.59). The options, which have a 10-year term, will vest over four years, with 25% vesting on the first anniversary of the grant date. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance employee retention and incentivize performance.

Optinose (NASDAQ:OPTN) has successfully closed its underwritten public offering of 28,750,000 shares at $1.60 per share, raising gross proceeds of $46.0 million. The offering included the full exercise of the underwriters' option for an additional 3,750,000 shares. The net proceeds will primarily fund working capital, general corporate purposes, and the commercialization and clinical development of XHANCE for chronic sinusitis. The offering followed a shelf registration statement filed with the SEC.

Optinose (NASDAQ:OPTN) has priced an underwritten public offering of 25 million shares at $1.60 per share, generating $40 million in gross proceeds before expenses. The offering is expected to close around November 18, 2021, pending customary conditions. Proceeds will fund working capital and support XHANCE's commercialization and clinical development for chronic sinusitis. Additionally, underwriters have a 30-day option to purchase 3.75 million shares at the offering price.

Optinose (NASDAQ:OPTN) announces plans for an underwritten public offering of common stock. All shares will be sold by the company, with an option for underwriters to purchase an additional 15% within 30 days. Proceeds will be used for working capital, general corporate purposes, and to support the commercialization and clinical development of XHANCE. The public offering price is yet to be determined and is subject to market conditions.

Optinose (NASDAQ:OPTN) reported a strong third quarter 2021 with XHANCE net revenue of $22 million, a 41% increase from Q3 2020. Total prescriptions rose 25% to 86,300, while new prescriptions increased by 22%. The company completed enrollment in pivotal trials for chronic sinusitis, expanding the potential patient base from 1 million to 3 million.

However, full-year 2021 net revenue guidance was reduced to $71-$75 million from at least $80 million. Operating expenses are projected at $132-$137 million. Cash reserves stand at $84.2 million.

Optinose (NASDAQ:OPTN) will report its Q3 2021 financial results and corporate updates on November 15, 2021, after market close. A conference call to discuss these results is scheduled for November 16, 2021, at 8:30 a.m. Eastern Time. Investors can participate by dialing (866) 916-4761 in the U.S. or +1 (409) 216-6496 outside the U.S. A simultaneous webcast will be available on the Company's website. A replay will be accessible until November 23, 2021. For more details, visit www.optinose.com.

Optinose (NASDAQ: OPTN) has completed recruitment for its second Phase 3b trial of XHANCE (fluticasone propionate) nasal spray targeting chronic sinusitis (CS), a condition affecting 30 million adults in the U.S. The company anticipates topline results from the first trial in Q1 2022 and from the second in Q2 2022, aiming for FDA approval of XHANCE as the first drug treatment for CS. This approval could significantly expand business opportunities and provide relief for many patients.

Optinose (NASDAQ:OPTN) has announced that CEO Peter Miller will present a company overview and update at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET. Interested parties can access the live webcast on the Investors page of the Optinose website, with a replay available for 30 days post-event. The company specializes in providing solutions for patients treated by ENT and allergy specialists.

OptiNose, Inc. (NASDAQ:OPTN) announced the grant of non-qualified stock option awards to seven new employees. A total of 60,000 shares were awarded to incentivize employment acceptance. The options were granted outside the company’s 2010 Stock Incentive Plan, adhering to Nasdaq Rule 5635(c)(4). Exercise prices were set at $2.51 and $2.57, corresponding to closing prices on grant dates of August 16 and 23, 2021. These options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining in monthly installments.